Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(3.99)
# 1,777
Out of 5,081 analysts
81
Total ratings
39.4%
Success rate
12.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Reiterated: Buy | $100 | $28.30 | +253.36% | 13 | Oct 23, 2026 | |
| RZLT Rezolute | Upgraded: Buy | n/a | $3.82 | - | 7 | Oct 5, 2026 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | n/a | $18.49 | - | 1 | Aug 24, 2026 | |
| NVAX Novavax | Reiterated: Buy | $18 | $9.40 | +91.49% | 3 | Aug 6, 2026 | |
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $8.06 | +393.18% | 1 | Jun 29, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $220 → $272 | $144.06 | +88.81% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $1.83 | - | 3 | Apr 15, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $43 | $44.44 | -3.24% | 1 | Mar 11, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $2.24 | - | 1 | Dec 18, 2025 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | n/a | $79.33 | n/a | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.21 | n/a | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.5054 | n/a | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $51.09 | n/a | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.91 | n/a | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.70 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $0.8498 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.75 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.27 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $10.00 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.89 | n/a | 3 | Jun 23, 2023 |
Vera Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $100
Current: $28.30
Upside: +253.36%
Rezolute
Oct 5, 2026
Upgraded: Buy
Price Target: n/a
Current: $3.82
Upside: -
Nuvectis Pharma
Aug 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $18.49
Upside: -
Novavax
Aug 6, 2026
Reiterated: Buy
Price Target: $18
Current: $9.40
Upside: +91.49%
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $8.06
Upside: +393.18%
Axsome Therapeutics
May 4, 2026
Reiterated: Buy
Price Target: $220 → $272
Current: $144.06
Upside: +88.81%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $1.83
Upside: -
Alkermes
Mar 11, 2026
Reiterated: Buy
Price Target: $43
Current: $44.44
Upside: -3.24%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.24
Upside: -
Dianthus Therapeutics
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $79.33
Upside: n/a
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.21
Upside: n/a
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.5054
Upside: n/a
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $51.09
Upside: n/a
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $9.91
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.70
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $0.8498
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $1.75
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.27
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $10.00
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $17.89
Upside: n/a